This antibody recognises CD221, a 155 kDa receptor tyrosine kinase, also known as Insulin-like growth factor I receptor (IGF-I Receptor). CD221 is composed of two extracellular alpha-subunits and two transmembrane betasubunits. Clone 1H7 recognises an epitope in the alpha subunits of CD221, demonstrated by Western blotting. CD221 is expressed in a range of tissues, including kidney, liver, placenta, mammary gland, brain, ovary and skin. The ligands for CD221 include IGF-I and IGF-II, which bind to CD221 and activate tyrosine kinase activity, resulting in phosphorylation of several intracellular signalling proteins. Clone 1H7 is reported to partically block binding of IGF-I and IGF-II to CD221. We recommend the use of BM2226LE for this purpose.
Purification
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Western Blot. Immunohistochemistry on paraffin sections: 1/10-1/40, This product requires proteindigestion pre-treatment of paraffin sections. Flow Cytometry: Use 10 μL of 1/10 diluted antibody to label 10^6 cells in 100 μL. Positive Control: Pancreas, placenta. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Beuschlein, Jakoby, Mentz, Zambetti, Jung, Reincke, Süss, Hantel: "IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma." in: Molecular and cellular endocrinology, Vol. 428, pp. 82-8, (2016) (PubMed).
de Wit, van Dalum, Lenferink, Tibbe, Hiltermann, Groen, van Rijn, Terstappen: "The detection of EpCAM(+) and EpCAM(-) circulating tumor cells." in: Scientific reports, Vol. 5, pp. 12270, (2015) (PubMed).
Hantel, Lewrick, Reincke, Süss, Beuschlein: "Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma." in: The Journal of endocrinology, Vol. 213, Issue 2, pp. 155-61, (2012) (PubMed).
Hantel, Lewrick, Schneider, Zwermann, Perren, Reincke, Süss, Beuschlein: "Anti insulin-like growth factor I receptor immunoliposomes: a single formulation combining two anticancer treatments with enhanced therapeutic efficiency." in: The Journal of clinical endocrinology and metabolism, Vol. 95, Issue 2, pp. 943-52, (2010) (PubMed).
There are two kinds of IGF receptors based on their relative affinities for IGF1 versus IGF2. The IGF1 receptor (also known as CD221) prefers IGF1 over IGF2 and weakly binds insulin. IGF1 receptor is a disulfide-linked heterotetrameric transmembrane protein consisting of two alpha (130 kD) and two beta (95 kD) subunits. Both the alpha and beta subunits are encoded within a single receptor precursor cDNA. The IGF1 receptor is therefore similar in structure to the insulin receptor. The proreceptor polypeptide is proteolytically cleaved and disulfide-linked to yield the mature heterotetrameric receptor. The IGF1 receptor is highly expressed in all cell types and tissues and is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival.Synonyms: IGF-I receptor, IGF1 Receptor, Insulin-like growth factor 1 receptor